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The recently discovered human bocavirus (HBoV) is the first member of the family Parvoviridae, genus
Bocavirus, to be potentially associated with human disease. Several studies have identified HBoV in respiratory
specimens from children with acute respiratory disease, but the full spectrum of clinical disease and the
epidemiology of HBoV infection remain unclear. The availability of rapid and reliable molecular diagnostics
would therefore aid future studies of this novel virus. To address this, we developed two sensitive and specific
real-time TaqMan PCR assays that target the HBoV NS1 and NP-1 genes. Both assays could reproducibly
detect 10 copies of a recombinant DNA plasmid containing a partial region of the HBoV genome, with a
dynamic range of 8 log units (101 to 108 copies). Eight blinded clinical specimen extracts positive for HBoV by
an independent PCR assay were positive by both real-time assays. Among 1,178 NP swabs collected from
hospitalized pneumonia patients in Sa Kaeo Province, Thailand, 53 (4.5%) were reproducibly positive for
HBoV by one or both targets. Our data confirm the possible association of HBoV infection with pneumonia and
demonstrate the utility of these real-time PCR assays for HBoV detection.
The parvoviruses of vertebrates are classified within the fam-
ily Parvoviridae, subfamily Parvovirinae, and further into five
genera, including Parvovirus, Erythrovirus, Dependovirus, Am-
dovirus, and Bocavirus (9). Until recently, parvovirus B19,
within the genus Erythrovirus, was the only parvovirus recog-
nized to cause human disease. This has changed with the dis-
covery of a new parvovirus that has been identified in respira-
tory specimens from young Swedish children with lower
respiratory tract infections (LRTIs) (1). Provisionally named
human bocavirus (HBoV), due to its genetic similarities to
other members of the Bocavirus genus, this virus has now been
identified in respiratory specimens from children with upper
and LRTI from Australia (8), Canada (2), France (6), and
Japan (7). The prevalence of HBoV among children with re-
spiratory disease reported in these studies ranges from 1.5 to
5.7%. However, the causal role of HBoV in LRTI, the full
spectrum of clinical disease, and the epidemiology of HBoV
infections still need to be defined.
To date, HBoV has not been successfully cultured, no serolog-
ical tests are yet available, and only conventional PCR assays have
been described. Real-time PCR, in contrast to conventional as-
says, offers rapid results, potentially increased sensitivity and spec-
ificity of detection, is less prone to false-positive results from
amplicon contamination, and is more amenable for quantitative
estimation of viral load (3). In this study, we developed real-time
PCR assays targeting the HBoV NS1 and NP-1 genes and used
these assays to test for HBoV in a large collection of respiratory
specimens from hospitalized pneumonia patients in Thailand.
(Data from the manuscript were presented in part at the
International Conference on Emerging Infectious Diseases,
Atlanta, Ga., 19 to 22 March 2006.)
MATERIALS AND METHODS
Clinical specimens. Respiratory specimens were collected from 1,178 hospi-
talized pneumonia patients identified through active population-based surveil-
lance for pneumonia in Sa Kaeo Province, Thailand, between 1 September 2004
and 31 August 2005 (S. J. Olsen, Y. Laosiritaworn, S. Siasiriwattana, S. Chun-
suttiwat, and S. F. Dowell, submitted for publication). The protocol underwent
institutional ethical review and was approved by the Thailand Ministry of Health
and the Centers for Disease Control and Prevention (CDC). Nasopharyngeal
swabs were collected in chilled viral transport medium and frozen at 70°C
within 48 h of collection. Two 300-l aliquots of each specimen were then added
to duplicate vials containing AL extraction buffer (QIAGEN, Valencia, CA) and
shipped on dry ice to the CDC for PCR testing for respiratory pathogens. Upon
receipt, total nucleic acid was extracted from one aliquot of each specimen by
using the automated BioRobot MDx (QIAGEN) following the manufacturer’s
instructions. Nucleic acid eluates (80 l) were supplemented with 100 l of
RNA storage buffer (Ambion, Austin, TX), split into two aliquots, and stored at
70°C until PCR testing.
DNA extracts of respiratory specimens from 12 patients that had previously
tested positive or negative for HBoV by an independent PCR assay (developed
at the Qpid Laboratory, SASVRC, Royal Children’s Hospital, Queensland, Aus-
tralia) (8) were shipped to the CDC on dry ice for confirmatory testing.
Primers and probes. Conserved regions of the HBoV NS1 and NP-1 genes were
identified from alignments of nucleotide sequences available from GenBank (for
NS1, DQ206700-08, DQ000495-96, and DQ200648, and for NP-1, DQ000495-96,
AB243566-72, DQ296618-35, DQ353695-99, DQ299885, DQ267760-75, DQ284856,
DQ295844, and AM109958-66) using ClustalW (4). Primer and probe sets were
designed to these conserved regions using Primer Express software, version 2.0.0
(Applied Biosystems, Foster City, CA). The best primer and probe sets selected by
the software that showed no major nonspecific homologies by BLAST (Basic Local
Alignment Search Tool) analysis were synthesized by the CDC Biotechnology Core
Facility using standard phosphoramidite chemistry. TaqMan probes were labeled at
the 5 ends with the reporter molecule 6-carboxyfluorescein and at the 3 ends with
Black Hole Quencher 1 (Biosearch Technologies, Inc., Novato, CA). Optimal
primer and probe concentrations were determined by checkerboard titrations
against the HBoV plasmid (see below). Primer and probe sets that gave the highest
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amplification efficiencies at optimized conditions and with no detectable cross-
reactions were chosen for further study (Table 1).
Plasmid standard construction. A 1,298-bp DNA subgenomic fragment of
HBoV was amplified from a positive nasal swab by using primers bracketing the
real-time PCR target regions in the NS1 and NP-1 genes (forward, 5-CCTGT
GCTGTGTCCTGAACAAAC-3, and reverse, 5-CAATGCGAGTAGAGTGC
CAGTAGAAC-3). The product was cloned into plasmid vector pCRII-TOPO
(Invitrogen, Carlsbad, CA) and sequenced for verification (GenBank accession
no. DQ499604). The pCRII HBoV plasmid was purified using a QIAprep mini
prep kit (QIAGEN) and quantified by UV spectroscopy (4.1  1010 copies/l).
To generate standard curves for quantitative determinations and to access am-
plification efficiency, replicate serial 10-fold dilutions of the pCRII HBoV plas-
mid were prepared in 10 mM Tris-EDTA buffer containing 100 g/ml herring
sperm DNA (Promega, Madison, WI) and stored at 20°C until use. To mini-
mize potential for contamination, HBoV plasmid DNA was prepared in a sep-
arate laboratory.
HBoV real-time PCR assays. The real-time PCR assays were performed using
iQ Supermix (Bio-Rad, Hercules, CA) with each 25-l reaction mixture contain-
ing 0.5 M forward and reverse primers, 0.1 M probe, and 5 l of nucleic acid
extract. Amplification was carried out in 96-well plates on an iCycler iQ real-time
detection system (Bio-Rad). Thermocycling conditions consisted of 3 min at 95°C
for activation of the iTaq DNA polymerase and 45 cycles of 15 s at 95°C and 1
min at 60°C. Each run included one synthetic template control and one no-
template control for each target. Specimen extracts were also tested by real-time
PCR for the human RNase P gene to monitor specimen quality and the presence
of PCR inhibitors as previously described (5). A positive test for both NS1 and
NP-1 targets or for a single target confirmed from a second extraction from a new
sample aliquot was considered definitive evidence of HBoV infection.
Conventional HBoV PCR. Real-time HBoV PCR assays were compared with
a conventional PCR assay using NS1 gene primers HBoV01.2 and HBoV02.2
and protocol as previously described by Sloots et al. (8), with amplification
performed on the GeneAmp PCR System 9700 (Applied Biosystems). The re-
sulting 291-bp amplicon was identified by gel electrophoresis and ethidium bro-
mide staining.
RESULTS
Real-time PCR amplification efficiency. Optimized PCR as-
says targeting conserved regions of the NS1 and NP-1 genes
were further evaluated for amplification efficiency and limit of
FIG. 1. NS1 and NP-1 real-time PCR assays showing representative results obtained with serial 10-fold dilutions (101 to 108 copies per reaction)
of the pCRII HBoV plasmid. The top panels show baseline subtractive curve fit views of the data with relative fluorescence units (RFU) plotted
against cycle number. The default setting of 10 times the standard deviation of the RFU measured in all wells over the baseline cycles was used
to calculate the CT for a positive reaction (horizontal line). The bottom panels show standard curve analysis of the DNA amplification plots with
CT values plotted proportionately against the logarithm of the input copy number. The dynamic range of NS1 and NP-1 PCR assays spans 8 log
units with slopes of 3.3 and an R2 value of 1.0.
TABLE 1. HBoV primers and probes used in real-time PCR assays
Gene target Primer/probea Sequence (5 to 3) Ampliconlength (bp) Position
b
NS1 Primer, fwd TGC AGA CAA CGC YTA GTT GTT T 88 1554–1575
Primer, rev CTG TCC CGC CCA AGA TAC A 1641–1623
Probe CCA GGA TTG GGT GGA ACC TGC AAA 1598–1621
NP-1 Primer, fwd AGA GGC TCG GGC TCA TAT CA 81 2478–2497
Primer, rev CAC TTG GTC TGA GGT CTT CGA A 2558–2537
Probe AGG AAC ACC CAA TCA RCC ACC TAT CGT CT 2500–2528
a Probes 5 end labeled with 6-carboxyfluorescein and 3 end labeled with Black Hole Quencher. fwd, forward; rev, reverse.
b Nucleotide numbering based on HBoV strain st1 (accession no. DQ000495).










target detection. PCR amplification of serial 10-fold dilutions
of the pCRII HBoV plasmid achieved 95% efficiency with
linear amplification over an 8-log dynamic range from 101 to
108 copies per reaction for both primer/probe sets (Fig. 1;
Table 2). To assess the effect of exogenous nucleic acid extract
on the amplification efficiency, 10-fold serial dilutions of the
pCRII HBoV plasmid were prepared in pooled total nucleic
acid extracted from seven HBoV-negative nose and throat
swabs and sputum specimens collected from laboratory staff.
Exogenous nucleic acid from respiratory specimens showed a
minimal effect on the amplification efficiencies of both primer/
probe sets (Table 2).
Real-time PCR limit of detection. To assess the limit of
detection of the NS1 and NP-1 assays, 1, 5, and 10 copies of the
pCRII HBoV plasmid per reaction were tested in 18 replicates.
At 10 copies, 100% of the replicates were positive by both
assays, at 5 copies, 10 (56%) NS1 and 11 (61%) NP-1 replicates
were positive, and at 1 copy, 7 (39%) NS1 and 5 (28%) NP-1
replicates were positive.
Real-time PCR reproducibility. To assess the intra- and in-
terassay reproducibility, 10-fold serial dilutions of the pCRII
HBoV plasmid from 101 to 108 copies per reaction were tested
in triplicate on three different days. Over the linear range of
the assays, the coefficient of variation of the mean cycle thresh-
old (CT) values within runs ranged from 0.20 to 1.88% and 0.28
to 0.86% and from run to run ranged from 0.33 to 2.12% and
0.94 to 2.79% for the NS1 and NP-1 real-time PCR assays,
respectively (Table 3).
Real-time PCR specificity. The specificity of the real-time
PCR assays was assessed by testing nucleic acid extracts of
pooled respiratory specimens containing human and microbi-
ological flora DNA as well as DNA from laboratory cultures or
positive clinical specimens containing human pathogens that
may colonize the respiratory tract, including human parvovirus
B19, adenovirus, herpes simplex virus 1, Mycoplasma pneu-
moniae, and Chlamydia pneumoniae.
Because we anticipate incorporating the HBoV real-time
PCR assays into a respiratory pathogen assay panel that in-
cludes a reverse transcription step, we also tested cDNA pre-
pared from laboratory strains of RNA viruses, including hu-
man respiratory syncytial virus, parainfluenza viruses 1, 2, and
3, rhinovirus 1A, and influenza viruses A and B. No specific
amplification was detected by either NS1 or NP-1 assay from
any of the above samples.
Comparison of real-time and conventional PCR. Tenfold
serial dilutions of the pCRII HBoV plasmid were tested in
parallel by the real-time PCR assays and a conventional
PCR assay that amplifies a 279-bp region of the NS1 gene




CV (%) for no. of pCRII HBoV plasmid DNA for
indicated copies/reactiona
101 102 103 104 105 106 107 108
NS1
Intraassayb 1.88 0.46 0.2 0.34 0.68 0.45 0.73 0.77
Interassay (%)c 2.12 1.51 0.33 0.55 0.52 0.79 1.41 1.36
NP-1
Intraassay (%) 0.86 0.55 0.46 0.29 0.49 0.28 0.33 0.61
Interassay (%) 2.32 1.69 1.25 0.94 1.95 2.02 2.76 2.79
a Tenfold serial dilutions of HBoV plasmid DNA; dilution series thawed on
three different days and assays performed in triplicate for each dilution. CV,
coefficient of variation.
b Determined from three replicates within each assay.
c Determined from three independent assays performed on different days.
TABLE 4. HBoV real-time PCR results from 12 blinded
sample extractsa




BRIS001B Neg Neg Neg
BRIS002B Pos 12.9 13.3
BRIS003B Pos 32.8 31.9
BRIS004B Neg Neg Neg
BRIS005B Pos 27.7 27.5
BRIS006B Pos 37.0 37.6
BRIS007B Pos 34.4 35.1
BRIS008B Pos 19.1 19.5
BRIS009B Neg Neg Neg
BRIS010B Pos 35.7 36.7
BRIS011B Neg Neg Neg
BRIS012B Neg Neg Neg
a ID, identification no. Neg, negative; pos, positive.
b See reference 8 for details.
c Results (CT values) from 1 l of a 1:10 dilution of DNA extract tested.
TABLE 2. Efficiency of HBoV real-time PCR assays
Target and
efficiency type
Mean CT valuesa at estimated pCRII HBoV plasmid DNA copy no.




37.08  0.70 33.68  0.16 30.67  0.06 27.53  0.09 23.92  0.16 20.68  0.09 17.49  0.13 13.98  0.11 3.29 101.3
Plasmid with
extract




37.18  0.32 34.86  0.19 31.37  0.15 27.77  0.08 24.61  0.12 21.21  0.09 17.86  0.06 14.63  0.09 3.29 101.3
Plasmid with
extract
38.87  0.28 35.08  0.15 31.61  0.25 28.26  0.19 25.16  0.49 21.59  0.04 18.16  0.04 14.73  0.09 3.41 96.3
a Values shown are means of triplicate samples  standard deviations.
b Slope determined from the formula Y 	 Y intercept  slope log10. Slopes calculated from 101 to 108 copies per reaction.
c Efficiency 	 
10(1/slope)  1.
d Reactions performed in presence of pooled total nucleic acid extract from seven human respiratory specimens.










(8). The detection limits for both assays were identical. Of
12 blinded clinical specimen extracts previously tested by
the conventional PCR, 7 positive and 5 negative for HBoV
DNA were correctly identified by both real-time PCR assays
(Table 4).
Real-time PCR results from patients with pneumonia. Of
the 1,178 respiratory specimens from hospitalized patients with
pneumonia in Sa Kaeo Province, Thailand, 32 were PCR pos-
itive for both NS1 and NP-1 targets and 39 were positive for
only a single target (23 for NS1 and 16 for NP-1). On retesting
from a second, previously unopened specimen aliquot, 14 of
the 39 single-target positive specimens were positive for both
targets, 2 were positive by another target only, and 5 were
positive by the same target only. Eighteen samples positive for
a single target on initial testing could not be confirmed from
the second sample aliquot. The CT values obtained for NS1-
and NP-1-positive specimens were highly correlated (R2 	
0.966) and ranged from 16.4 to 38.8 and from 16.7 to 40.7,
respectively (Fig. 2). The CT values of all single-target positive
specimens were near the assay detection limit (CT  37).
Altogether, 53 (4.5%) of the patients had detectable HBoV
DNA based on our positive test criteria.
DISCUSSION
The objective of the study was to develop real-time PCR
assays for HBoV that would be suitable for diagnostic appli-
cations. Given the limited sequence data currently available for
the virus, and in anticipation of possible sequence variation
among unrecognized HBoV strains, two discrete targets were
selected from conserved regions of the virus nonstructural pro-
tein genes for assay development. The assays performed equiv-
alently, with a reproducible detection limit of 10 target genome
copies per reaction and linear amplification over a wide dy-
namic range suitable for quantitative applications.
The potential for contamination with HBoV DNA that
could lead to false-positive results was a major concern in
this study. This concern was heightened by our finding of a
predominance of high CT values (low genome copy number)
and a high proportion of single-target positives among the
study specimens. This was partially addressed by using real-
time PCR assays that benefit from a closed tube system that
minimizes the potential for amplicon contamination and by
requiring two independent assay targets (NS1 and NP-1) to
be positive in the same sample aliquot or a single assay
target to be positive from two independent sample extracts
for the sample test result to be considered positive. In ad-
dition, we rigorously followed recommended laboratory
practices that promote a DNA contamination-free environ-
ment (3), including strict separation of pre- and post-PCR
activities and by conducting routine surveillance for contam-
ination by ample use of negative PCR controls. Plasmid
control DNA handling and PCR setup activities were done
in separate rooms, and extractions of clinical specimens
were performed prior to the introduction of any artificial
HBoV DNA into our laboratory.
The prevalence of HBoV infection found among Thai pa-
tients hospitalized with pneumonia (4.5%) was similar to prev-
alence estimates previously reported for children with LRTI
(1, 7, 8), although this likely represents an underestimate of the
true number of positive specimens. As noted above, most of
the HBoV PCR-positive patients had relatively low virus loads.
We found no evidence from the RNase P extraction control
(data not shown) of poor specimen quality or the presence of
PCR inhibitors or that delays in timing of specimen collection
from onset of symptoms could account for these findings. We
therefore conclude that HBoV may often be present in respi-
ratory specimens from patients with pneumonia at low levels,
thus highlighting the importance of using sensitive PCR assays
and testing replicates of two or more targets to ensure the
detection of HBoV.
In conclusion, we have developed sensitive and specific real-
time PCR assays with which we confirmed the presence of
HBoV DNA in patients hospitalized with pneumonia. The
availability of these assays and the pCRII HBoV plasmid con-
trol will facilitate further studies to better define the epidemi-
ology of HBoV infection and its role in human disease.
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